Cite
HARVARD Citation
Ruckwardt, T. et al. (2021). Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet. 9 (10), pp. 1111-1120. [Online].